Results 1 to 10 of about 1,437,202 (311)

Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections [PDF]

Clinical Pharmacokinetics, 2021
Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to progressive and life-threatening disease of multiple organs. Several factors such as increased testing and prevalence have made this an emerging infectious disease ...
Jan‐Willem C. Alffenaar, Anne‐Grete Märtson, Scott K. Heysell, Jin‐Gun Cho, Asad E. Patanwala, Gina Burch, Hannah Y. Kim, Marieke G. G. Sturkenboom, Anthony Byrne, Debbie Marriott, Indy Sandaradura, Simon Tiberi, Vitali Sintchencko, Shashikant Srivastava, Charles A. Peloquin   +14 more
openalex   +2 more sources

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Clinical Pharmacokinetics, 2023
Although kinase inhibitors (KI) frequently portray large interpatient variability, a ‘one size fits all’ regimen is still often used. In the meantime, relationships between exposure-response and exposure-toxicity have been established for several KIs, so
Maud B. A. van der Kleij, Niels A. D. Guchelaar, R. Mathijssen, J. Versluis, A. Huitema, S. Koolen, N. Steeghs   +6 more
semanticscholar   +1 more source

Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy

Biosensors, 2023
Precision medicine, particularly therapeutic drug monitoring (TDM), is essential for optimizing drug dosage and minimizing toxicity. However, current TDM methods have limitations, including the need for skilled operators, patient discomfort, and the ...
Yuqiao Liu, Jun Yu Li, Shenghao Xiao, Yanhui Liu, Mingxia Bai, Lixiu Gong, Jiaqian Zhao, Dajing Chen   +7 more
semanticscholar   +1 more source

Dried Blood Spots—A Platform for Therapeutic Drug Monitoring (TDM) and Drug/Disease Response Monitoring (DRM)

European journal of drug metabolism and pharmacokinetics, 2023
This review provides an overview on the current applications of dried blood spots (DBS) as matrices for therapeutic drug (TDM) and drug or disease response monitoring (DRM).
Nur Nabihah Binte Zailani, P. Ho
semanticscholar   +1 more source

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Therapeutic Drug Monitoring, 2021
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under ...
S. Bergan, M. Brunet, D. Hesselink, K. Johnson-Davis, P. Kunicki, F. Lemaitre, P. Marquet, M. Molinaro, Ofelia Noceti, S. Pattanaik, T. Pawiński, C. Seger, M. Shipkova, J. Swen, T. van Gelder, R. Venkataramanan, E. Wieland, J. Woillard, Tom C. Zwart, M. Barten, K. Budde, M. Dieterlen, L. Elens, V. Haufroid, S. Masuda, O. Millán, T. Mizuno, D. Moes, M. Oellerich, N. Picard, Linda Salzmann, B. Tönshoff, R. V. van Schaik, N. T. Vethe, A. Vinks, P. Wallemacq, A. Åsberg, L. Langman   +37 more
semanticscholar   +1 more source

Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Pharmaceutics, 2022
Background: To promote model-informed precision dosing (MIPD) for vancomycin (VCM), we developed statements for therapeutic drug monitoring (TDM). Methods: Ten clinical questions were selected.
Kazuaki Matsumoto, Kazutaka Oda, K. Shoji, Yuki Hanai, Yoshiko Takahashi, Satoshi Fujii, Y. Hamada, Toshimi Kimura, T. Mayumi, T. Ueda, K. Nakajima, Y. Takesue   +11 more
semanticscholar   +1 more source

Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19

Therapeutic Drug Monitoring, 2022
: Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for the treatment of mild-to-moderate COVID-19.
F. Lemaitre, K. Budde, T. van Gelder, S. Bergan, Roland Lawson, Ofelia Noceti, R. Venkataramanan, L. Elens, D. Moes, D. Hesselink, T. Pawiński, K. Johnson-Davis, B. D. de Winter, S. Pattanaik, M. Brunet, S. Masuda, L. Langman   +16 more
semanticscholar   +1 more source

Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.

Gastroenterology, 2022
Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases in order to maximise benefit and to reach more stringent, objective endpoints.
P. Irving, K. Gecse
semanticscholar   +1 more source

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics

Clinical pharmacology and therapy, 2021
Therapeutic drug monitoring (TDM) and model‐informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in individual patients with infections.
S. Wicha, A. Märtson, E. Nielsen, B. Koch, L. Friberg, J. Alffenaar, Iris K. Minichmayr   +6 more
semanticscholar   +1 more source

Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Frontiers in Public Health, 2022
Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval.
B. Lin, Yangmin Hu, P. Xu, Tao Xu, Chunyan Chen, Lei He, Mi Zhou, Z. Chen, Chunhong Zhang, Xuben Yu, L. Fang, Junfeng Zhu, Y. Ji, Qun Lin, He-qiong Cao, You-Jun Dai, Xiaoyan Lu, Changcheng Shi, Li Li, Changjiang Wang, Xumei Li, Qi Fang, Jing Miao, Zhengyi Zhu, Guangyong Lin, Haichao Zhan, Shiwen Lv, Yalan Zhu, Xin-jun Cai, Yinqing Ying, Meng Chen, Qiong Xu, Yiwen Zhang, Yubin Xu, Pea Federico, Saiping Jiang, Haibin Dai   +36 more
semanticscholar   +1 more source